Tirzepatide

Identity

Mechanism of action

Plain language

Tirzepatide activates two different gut-hormone receptors at once (GIP and GLP-1), which together produce stronger appetite suppression and blood-sugar control than hitting either one alone.

Technical

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist. It is a single peptide, not a combination of two drugs, engineered to bind and activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP receptor agonism contributes additional insulinotropic and adipose-tissue effects beyond GLP-1 agonism alone; the combined activation is associated with greater weight loss and glycemic effect in head-to-head and cross-trial comparisons than the GLP-1-monoagonist class. The C20 fatty diacid enables albumin binding and a roughly 5-day half-life supporting once-weekly dosing.

Sources: Mounjaro (tirzepatide) FDA

What it’s used for

Approved

• Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes (Mounjaro).

  Sources: Mounjaro (tirzepatide) FDA

• Chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbidity, combined with reduced-calorie diet and increased physical activity (Zepbound).

  Sources: Zepbound (tirzepatide) FDA

• Moderate-to-severe obstructive sleep apnea in adults with obesity, approved December 20, 2024, the first drug approved for this indication, based on the SURMOUNT-OSA trial (Zepbound).

  Sources: Zepbound (tirzepatide) FDA, Sleep Foundation: Zepbound, Eli Lilly investor

Human trials, not approved for this use

• Tirzepatide reduces alcohol consumption in people with obesity, per observational and early trial data.

  Sources: PMC review, semaglutide

Off-label / community use

• Widespread off-label prescribing for weight loss outside the labeled obesity or overweight-plus-comorbidity population.

  Sources: Jastreboff AM, et, 2022

• Polycystic ovary syndrome (PCOS)-related insulin resistance and androgen excess is discussed as an emerging off-label use in commercial and clinic commentary, but no completed phase 3 PCOS trial for tirzepatide was identified; treat as anecdotal or commercial framing, not trial evidence, until a specific trial citation exists.

  Sources: Doctronic, commercial clinic

Pharmacokinetics

Reconstitution

Worked example

The FDA-approved product (Mounjaro, Zepbound) ships ready-to-use as single-dose pens/vials (2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL) or multi-dose KwikPens and is never lyophilized; the figures here apply only to the separate compounded or research-chemical vial form sold during the 2023-2024 tirzepatide shortage, reconstituted by the buyer, and every figure is a commercial claim, not FDA data. Section 503A/503B compounding of a copy of a commercially available drug is legally permitted only while that drug appears on the FDA drug shortage list; the research document dates the U.S. tirzepatide shortage to 2023-2024, so the shortage-based legal basis for this market closed in 2024. Using a commonly advertised 30 mg vial reconstituted with 3 mL of bacteriostatic water: concentration = 30 mg / 3 mL = 10 mg/mL. At this concentration, 1 U-100 syringe unit (0.01 mL) = 0.1 mg. Converting the FDA-labeled injectable titration steps to units: 2.5 mg (start) = 25 units; 5.0 mg = 50 units; 7.5 mg = 75 units; 10.0 mg = 100 units; 12.5 mg = 125 units, which exceeds a standard 100-unit (1 mL) U-100 syringe; 15.0 mg (maximum) = 150 units, which also exceeds a standard 100-unit (1 mL) U-100 syringe. This is a real practical constraint at this vendor concentration, not a rounding artifact: the two highest labeled maintenance doses cannot be drawn into a single standard 1 mL insulin syringe. Vendor guidance addressing this explicitly recommends switching to a more concentrated reconstitution (for example 20 mg/mL, which would put 12.5 mg at 62.5 units and 15 mg at 75 units) for patients titrating to the top of the range.

Sources: SeekPeptides tirzepatide reconstitution, Fifty410 FAQ: understanding

Storage and post-reconstitution stability

Unopened storage

Before first use, refrigerate 2-8C (36-46F); do not freeze; may be stored at room temperature up to 86F (30C) for up to 21 days before first use (Mounjaro label language). In-use: Mounjaro, refrigerate after first use and use within 21 days; Zepbound, discard 30 days after first use, after four weekly doses, or 30 cumulative room-temperature days, whichever comes first; once moved to room temperature, do not return to the refrigerator.

Post-reconstitution stability – Vendor claim

approximately 28 days refrigerated at 2-8C. 2-8C, refrigerated

Sources: GLP3 Planner tirzepatide

No citable figure. This is a commercial claim, not an FDA-established figure; no regulatory-grade post-reconstitution stability data exists for the compounded vial form.

Safety

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

  Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA

• Known serious hypersensitivity to tirzepatide or any excipient.

  Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA

Notable risks

• Severe gastrointestinal reactions; acute pancreatitis; acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy), reported in 0.6% of Mounjaro-treated patients versus 0% placebo in placebo-controlled trials.

  Sources: Search-aggregated FDA label, 2025

• Hypoglycemia, risk lowered by reducing concomitant sulfonylurea or insulin dose; acute kidney injury (postmarketing reports, some requiring hemodialysis, mostly in patients with GI-adverse-effect-driven dehydration); hypersensitivity reactions including anaphylaxis and angioedema.

  Sources: Search-aggregated FDA label, 2025

• Diabetic retinopathy complications in type 2 diabetes; suicidal behavior and ideation; pulmonary aspiration risk under general anesthesia or deep sedation, attributed to delayed gastric emptying.

  Sources: Search-aggregated FDA label, 2025, Eli Lilly medical

• Common adverse effects: nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions; dose-related, most pronounced during titration.

  Sources: Mounjaro (tirzepatide) FDA

• Monitoring: watch for pancreatitis and gallbladder symptoms; monitor renal function in patients with significant GI adverse effects; monitor blood glucose closely and adjust concomitant insulin or secretagogue doses when combined; screen for mood changes or suicidal ideation; discuss pre-procedure fasting and anesthesia risk given delayed gastric emptying.

  Sources: Search-aggregated FDA label, 2025, Eli Lilly medical

Sources

1. Mounjaro (tirzepatide) FDA label, via DailyMed
2. Zepbound (tirzepatide) FDA label, via DailyMed
3. Sleep Foundation: Zepbound approved to treat obstructive sleep apnea
4. Eli Lilly investor release, Zepbound obstructive sleep apnea approval
5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (2022)
6. PMC review, semaglutide and tirzepatide effects on alcohol consumption
7. Doctronic, commercial clinic commentary on tirzepatide off-label uses
8. SeekPeptides tirzepatide reconstitution chart (commercial)
9. Fifty410 FAQ: understanding compounded tirzepatide dosing, 20 mg/mL versus 10 mg/mL (commercial)
10. GLP3 Planner tirzepatide reconstitution guide (commercial)
11. Drugs.com medical answer: how long Zepbound can be left in the fridge
12. Search-aggregated FDA label warnings for tirzepatide (2025)
13. Eli Lilly medical information page on Mounjaro warnings and precautions
14. peptidedosages.com, Tirzepatide 5 mg vial dosage protocol